Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Why Dozens of Pro Athletes are Paying Attention to this Product (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Neuraxis Inc NRXS

Healthcare Medical Devices
Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:NRXS)

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

GlobeNewswire 6 days ago

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

GlobeNewswire November 12, 2024

NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024

GlobeNewswire November 5, 2024

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market

GlobeNewswire November 4, 2024

NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024

GlobeNewswire October 29, 2024

NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

GlobeNewswire October 22, 2024

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

GlobeNewswire September 19, 2024

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

GlobeNewswire August 27, 2024

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

GlobeNewswire August 13, 2024
View More News ››

Opinion & Analysis (NYSEAM:NRXS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:NRXS)

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expa

News; $NRXS NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable MarketCARMEL, Ind., Nov. 04, 2024 (GLOBE...
whytestocks - November 4, 2024
View more Bullboard ››

Vista Gold Corp.

Vista Gold Corp.

Vista Gold Corp. (NYSE American and TSX: VGZ) holds the Mt Todd gold project, a shovel-ready development-stage deposit ...
View More »